IGF-1R highly expressed lesions, such as malignant tumors, thyroid-associated ophthalmopathy, and proliferative diseases
Conditions
Interventions
Gold Standard:Detection of IGF1R expression by pathological IHC method
Index test:18F/68Ga/64Cu-SMIC-3001 PET
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 - 75 years old, gender not restricted; 2. Diagnosed with one of the following diseases through pathology or clinical examination: (1) Thyroid-associated ophthalmopathy (active stage) (2) Solid tumors with positive IGF-1R (confirmed by immunohistochemistry or genetic testing) (3) Other proliferative lesions suspected of having high IGF-1 expression based on clinical findings; 3. Expected survival period >= 6 months; 4. Basic normal function of major organs; 5. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Severe cardiovascular, liver or kidney dysfunction; 3. Received other anti-tumor treatments within 4 weeks; 4. Known to be allergic to monoclonal antibodies; 5. Severe infection or immunodeficiency diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| specificity;Sensitivity;accuracy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Negative Predictive Value;Positive Predictive Value;Correlation coefficient between SUVmax and IGF-1R expression level;Quality control and radiochemical purity of the radiopharmaceuticals; | — |
Countries
China
Contacts
Public ContactChao Ma
Shanghai Tenth People's Hospital
Outcome results
None listed